Resultado de búsqueda
Anne Wojcicki. Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was audacious: to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process. Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare and felt ...
10 de oct. de 2019 · Anne Wojcicki has accumulated the net worth of $440 million as an American entrepreneur, according to 2016 statistics. She has gathered revenues from her work as a healthcare consultant at Passport Capital, a San Francisco-based investment fund, and at Investor AB. Her stint on one of the world’s most exhaustive databases of personal genetic ...
23 de sept. de 2020 · AW. Anne Wojcicki is the cofounder and CEO of 23andMe, a pioneering direct-to-consumer DNA-testing firm. In 2013 the genetic testing firm 23andMe received a cease-and-desist letter from the U.S ...
7 de nov. de 2023 · 23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’. 23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more. Published Nov. 7, 2023. By Alexandra Pecci.
Anne Wojcicki es una de las millonarias más tacañas del planeta y una de las fundadoras de 23andme, una compañía que realiza test genéticos por 99 dólares, lo que ha generado una gran polémica en el mundo científico.
As a featured speaker in the Stanford Biodesign <i>From the Innovator’s Workbench</i> series, Wojcicki told the story of her groundbreaking company, 23andMe —from its origin through her decision to take the company public with a special-purpose acquisition company (SPAC) that raised nearly $600 million. Read the story here.
The Investor Relations website contains information about 23andMe, Inc.'s business for stockholders, potential investors, and financial analysts.
